Proveca Limited

With today’s major research and development activities of pharmaceutical companies focused on meeting the needs of an increasingly aging population, children who represent the bulk of the dependent population worldwide still remain a widely neglected niche market. The recognition of the rights of children to have access to safe and effective drugs and the...

Proveca plans to develop a novel oral formulation of glycopyrronium for the treatment of sialorrhea or Chronic Pathological Drooling (CPD) in children. CPD is a common and disabling manifestation of several neurological disorders including cerebral palsy and amyotrophic lateral sclerosis and for which no treatment is currently licensed. It is an often ove...

The recognition of the rights of children to have access to safe and effective drugs and the needs of healthcare providers to receive age-appropriate drug information continues to have a major effect on all areas of paediatric pharmaceuticals. In line with this challenge, Proveca’s objective is to develop a new dosage formula of an off patent immunosuppre...

Proveca is to develop a portfolio of licensed age appropriate formulations of off-patent medicines (i.e. not covered by a patent/supplementary certificate) for the treatment of cardiovascular diseases in children including hypertension and congenital heart disease. Amlodipine (calcium channel blocker), dipyridamole (antiplatelet) and bendroflumethiazide (...

Epilepsy has a high prevalence and impacts 0.5% to 1% of the paediatric population. In the UK there are an estimated 60,000 children under 18 with epilepsy. The estimated number of children and adolescents in Europe with active epilepsy is 0.9 million. Up to 30% of children still do not respond adequately to current drug therapies. Rather than relying on ...

With today’s major research and development activities of pharmaceutical companies focused on meeting the needs of an increasingly aging population, children who represent the bulk of the dependent population worldwide still remain a widely neglected niche market. The recognition of the rights of children to have access to safe and effective drugs and the...

Sialorrhea or Chronic Drooling (CD) in children is a significant problem and can occur as the manifestation of different neurological disorders such as cerebral palsy (CP) and amyotrophic lateral sclerosis (ALS). Proveca’s objective is to develop a novel oral formulation of glycopyrronium, an off-patent drug for the treatment of sialorrhea or Chronic Droo...

Acute pain is a significant problem and can occur following acute illness or disease processes, trauma or operative procedures. Proveca’s objective is to develop an intravenous (IV) formulation of an off-patent drug for the treatment of pain and fever in adults and children. They will undertake the required clinical studies and apply for a license to targ...

With today’s major research and development activities of pharmaceutical companies focused on meeting the needs of an increasingly aging population, children who represent the bulk of the dependent population worldwide still remain a widely neglected niche market The recognition of the rights of children to have access to safe and effective drugs and the ...